One group demonstrated that intratumoral injection of ADU S-100, a STING agonist, in a preclinical melanoma model promoted formation of CCL19+, CCL21+, PNAd+ TLS, although these TLS did not contain significant B cell infiltration or GCs (159). Here, STING1 is linked to melanoma.